6533b7dbfe1ef96bd1270c17

RESEARCH PRODUCT

The Impact of 68Ga-PSMA PET/CT and PET/MRI on the Management of Prostate Cancer.

I. RichardsenChristian BauesManuela A HoffmannHelmut J. WielerNicholas J. KuntzMathias Schreckenberger

subject

MaleUrology030232 urology & nephrologyComputed tomographyGallium Radioisotopesurologic and male genital diseasesMultimodal ImagingManagement of prostate cancer03 medical and health sciences0302 clinical medicinePositron Emission Tomography Computed TomographymedicineOrganometallic CompoundsHumansGallium IsotopesMembrane antigenSalvage TherapyPET-CTMembrane Glycoproteinsmedicine.diagnostic_testbusiness.industry68ga psmaProstatic NeoplasmsMagnetic resonance imagingProstate carcinomaProstate-Specific AntigenMagnetic Resonance ImagingPositron emission tomography030220 oncology & carcinogenesisPositron-Emission TomographyNeoplasm Recurrence LocalRadiopharmaceuticalsbusinessNuclear medicine

description

Prostate-specific membrane antigen (PSMA) is a transmembrane protein with significantly increased expression in the cells and metastases of prostate carcinoma (CaP). PSMA-expression correlates with higher serum levels of prostate-specific antigen (PSA) and a higher Gleason score (GS). This finding has led to the development of novel imaging modalities such as 68Ga-/18F-labeled PSMA positron emission tomography/computed tomography (PET/CT) and positron emission tomography/magnetic resonance imaging (PET/MRI). This article reviews the literature pertaining to various new imaging technologies for the management of CaP. PSMA positron emission tomography/computed tomography appears to be an excellent diagnostic tool, that may drastically impact the management of a large number of patients with primary and recurrent CaP.

yearjournalcountryeditionlanguage
2018-11-01Urology
10.1016/j.urology.2019.04.004https://pubmed.ncbi.nlm.nih.gov/31195009